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Abstract: Infection and epithelial downgrowth are major problems associated with maxil-
lofacial percutaneous implants. These complications are mainly due to the improper closure of 
the implant–skin interface. Therefore, designing a percutaneous implant that better promotes 
the formation of a stable soft tissue biologic seal around percutaneous sites is highly desirable. 
Additionally, the fibroblast has been proven to play an important role in the formation of biologic 
seals. In this study, titania nanotubes were filled with 11.2 kDa C-terminal CCN2 (connective 
tissue growth factor) fragment, which could exert full CCN2 activity to increase the biological 
functionality of fibroblasts. This drug delivery system was fabricated on a titanium implant 
surface. CCN2 was loaded into anodized titania nanotubes using a simplified lyophilization 
method and the loading efficiency was approximately 80%. Then, the release kinetics of CCN2 
from these nanotubes was investigated. Furthermore, the influence of CCN2-loaded titania 
nanotubes on fibroblast functionality was examined. The results revealed increased fibroblast 
adhesion at 0.25, 0.5, 1, 2, 4, and 24 hours, increased fibroblast viability over the course of 
5 days, as well as enhanced actin cytoskeleton organization on CCN2-loaded titania nanotubes 
surfaces compared to uncoated, unmodified counterparts. Therefore, the results from this in 
vitro study demonstrate that CCN2-loaded titania nanotubes have the ability to increase fibro-
blast functionality and should be further studied as a method of promoting the formation of a 
stable soft tissue biologic seal around percutaneous sites.
Keywords: anodization, titania nanotubes, adhesion, connective tissue growth factor, 
fibroblast
Introduction
The long-term success of percutaneous implants relies on the formation of a stable soft 
tissue biologic seal around the percutaneous site.1–3 Infection and epithelial growth are 
two of the principal causes of the failure of percutaneous implants.1,3–9 A biosynthetic 
soft tissue seal can act as a barrier against epithelial downgrowth and bacterial invasion 
on subepithelial connective tissues and the implant interface.1,10,11
The fibroblast plays an important role in the formation of a biologic seal. 
The biologic seal of skin is provided by both the epidermis and the dermis, which 
mainly consist of fibroblasts that produce extracellular matrix (ECM) and various 
essential components of connective tissues, including glycosaminoglycans and 
c  ollagen in fibrous tissue.12,13 Previous studies have demonstrated that the quality 
of the   connective tissue at the percutaneous area is more important than the quality 
of the epithelial attachment for the long-term success of maxillofacial implants.11,14 
Therefore, expediting the attachment and growth of fibroblasts could promote the 
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formation of a permanent biologic seal at the percutaneous 
area and prevent contamination of the implant.15
Currently, the percutaneous surfaces of implants are 
often made smooth to prevent the adhesion of bacteria.11 
Upon healing, the wound closure is likely to be generated 
by the contraction of fibrous connective tissues during the 
healing process. However, such smooth surfaces have been 
shown to lead to detrimental capsule.9,11 Current methods to 
improve the formation of a biologic seal are aimed at pre-
venting bacterial infection rather than promoting skin growth 
around the percutaneous site. These methods include alter-
ing surgical techniques, modifying the implant design, and 
coating its surface.16 Coating approaches have been shown 
to increase the antibacterial ability of implants by using 
fibroblast growth factor 2-embedded apatite composites17 and 
silver nanoparticles.18,19 Although these coatings reduced the 
presence of bacteria compared to their uncoated counterparts, 
the infection rate was still high and there was no reported 
effect on biologic seal formation. Therefore, there is a need 
for alternate ways to improve the formation of a biologic 
seal and decrease infection rates. An alternative strategy is 
to create a growth factor coating that can promote fibroblast 
growth around the percutaneous site, which would not only 
provide a stable biological seal but would also provide a 
permanent barrier against bacterial infection. By optimizing 
the surface structure, as well as the growth factor loading 
capacity and release rate, biosynthetic coating materials can 
achieve both of these goals.
A more suitable drug carrier for creating a growth factor-
eluting implant coating is titania nanotubes, which have 
already been shown to exhibit very good biomechanical 
compatibility.16,20–22 This material has served as a carrier for 
several agents such as proteins, antibacterial compounds, 
and other drugs.18,22–25 In addition, titania nanotubes are 
highly ordered with different diameters and lengths that 
can be easily fabricated to specification.26 CCN2 (con-
nective tissue growth factor) is an excellent candidate for 
loading drugs. CCN2 has been shown to be sufficient to 
promote fibroblast adhesion, and it also promotes fibro-
blast proliferation.27–33 Recombinant human CNN2, a 
lower molecular weight isoform containing the 11.2 kDa 
C-terminal portion of the full length CNN2 protein, exerts 
full heparin binding, cell adhesion, and mitogenic CNN2 
activity. CNN2 is noncytotoxic at suitable doses and has 
satisfactory stability. Because the required dose of CNN2 
for biological activity is extremely low, it is possible 
to   fabricate coatings with extended delivery times by 
  controlling CNN2 release.
In this study, the purpose was to investigate whether 
CNN2 could be incorporated into the nanotubes controllably 
and to evaluate the effect of CNN2-loaded titania nanotubes 
on the biological responses of fibroblasts.
Materials and methods
Substrate preparation and anodization
Circular pure titanium sheets 1 mm thick and 10 mm in 
diameter were used as the substrates. The substrates were 
ultrasonically cleaned in acetone, followed by ethanol, and 
deionized water for 10 minutes, respectively. They were 
anodized for 120 minutes in an electrolyte containing 0.3 
weight percent hydrofluoric acid and 1 M/L phosphoric 
acid using a direct current power supply with a platinum 
electrode as the cathode. The anodization process took 
place at a constant voltage of 20 V and 25 V . The titanium 
substrates were rinsed with large amounts of deionized water 
immediately after anodization, air dried, and sterilized under 
ultraviolet light for 3 hours per substrate side prior to cell 
culture experiments.
Surface characterization
Topography and composition of the surface
Structural characterization of the titania nanotube surfaces 
was performed using a field emission scanning electron 
microscope (S-4800; Hitachi High Technologies, Tokyo, 
Japan). Images with a range of scan sizes were acquired from 
the top and cross-sections.
Roughness
For quantitative surface roughness analysis, atomic force 
microscopy (Veeco Germany, Mannheim, Germany) was 
performed on both nanotubular and unmodified surfaces. 
Measurements were conducted in ambient air with a scan 
rate of 2 Hz. The scan area was 0.5 × 0.5 µm2. Image 
analysis software was used to generate micrographs and to 
quantitatively compare the root mean square roughness and 
relative surface area of the nanotubular (20 V voltage) and 
unmodified titanium substrates.
Contact angle and surface free energy
Contact angle measurements were carried out by the sessile 
drop method on an EasyDrop Standard instrument (KRUSS 
GmbH, Hamburg, Germany) at room temperature. Three 
different liquids, ultrapure water, and diiodomethane were in 
the contact angle measurements. The surface free energy and 
its components were calculated using the van Oss acid–base 
method. The contact angle was measured by analyzing the 
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drop shape surface and the calculations of free energy using 
DSA1 software (KRUSS).
Fabrication of the titania nanotubular 
CNN2-loaded coating and release 
kinetics
Filling of the nanotubes
A simplified lyophilization method was chosen to load 
recombinant human CNN2 (PeproTech, Rocky Hill, NJ) 
into the nanotubes. This recombinant human CCN2, an 
11.2 kDa protein of 98 amino acid residues, is Escherichia 
coli-derived. A total of 5 µL of protein solution was pipetted 
onto the surface and spread to ensure even coverage. The 
surfaces were then allowed to dry under vacuum at room 
temperature in a freeze dryer for 2 hours. After drying, the 
loading step was repeated until the appropriate amount of 
protein (25 ng or 50 ng) was loaded. After the final drying 
step, excess drug was rinsed from the surface by pipetting 
500 mL of phosphate buffered saline (PBS) to analyze the 
loading efficiency.
Release of CCN2
To measure the release of the protein from the nanotubes, the 
surfaces were immersed in 500 µL of PBS in a 48-well plate 
at room temperature with orbital shaking at 70 rpm. A total of 
200 µL of samples was taken (replaced with 200 mL of fresh 
PBS) after specific intervals of time (15 minutes) for up to 
120 minutes to determine the release kinetics. The concentra-
tion of protein was monitored using a CCN2 enzyme-linked 
immunosorbent assay (PeproTech). The loading efficiency 
and the release kinetics for different doses of drug coatings 
were determined.
Cell culture
Primary human skin fibroblasts were isolated from newborn 
foreskin as previously described.34 Cells were used at pas-
sages three to eight. Human skin fibroblasts were cultured 
separately in HyClone Dulbecco’s Modified Eagle Medium 
(Thermo Fisher Scientific Inc, Pittsburg, PA) with HyClone 
10% fetal bovine serum (Thermo Fisher) and 1% penicillin/
streptomycin (Sigma-Aldrich Corporation, St Louis, MO) 
under standard culture conditions at 37°C in humidified 5% 
carbon dioxide/95% air. When the density of fibroblasts 
reached a suitable population, they were seeded onto the 
experimental substrates (50 ng CCN2-loaded 20 V voltage 
nanotubular coated surface, 20 V voltage nanotubular sur-
face, and unmodified surface were chosen as the experimental 
substrates), which were placed in a 48-well polystyrene plate 
and stored in a carbon dioxide incubator. The cell media was 
replaced every 2 days.
Cell viability assay
The concentration of cells seeded onto the specimen substrate 
was 1000 cells cm-2 per substrate for cell viability experi-
ments in a standard 48-well culture plate under standard cell 
conditions. Cell viability was assayed with a Cell Counting 
Kit-8 (Dojindo Molecular Technologies Inc, Kumamoto, 
Japan). Briefly, after 1, 3, and 5 days of culture, culture 
medium was moved, and 200 mL of fresh culture medium 
mixed with 20 µL of Cell Counting Kit-8 reagent was added 
into each well. Then, the samples were incubated for 2 hours 
according to the manufacturer’s instructions. In addition, the 
same volume of culture medium and Cell Counting Kit-8 
reagent without cells was also incubated as the background 
control. An aliquot (150 mL) of incubated medium was 
pipetted into a 96-well plate and the absorbance at 450 nm 
was measured for each well as above. All experiments were 
performed with a sample size of n = 6.
Cell adhesion assay
Cell adhesion was assayed with a live cell labeling kit 
(Cellstain-CFSE; Dojindo). The fibroblasts (107 cells/mL) 
were labeled with carboxyfluorescein diacetate succinimyl 
ester (20 µM/mL) at 37°C for 15 minutes. We pelleted cells 
by centrifugation and washed the cells by resuspending the 
pellet in fresh media. This process was repeated for a total of 
three washes. Then the fibroblasts were seeded at a density 
of 25,000 cells per substrate for adhesion experiments in a 
standard 48-well culture plate under standard cell condi-
tions. At the indicated time points (0, 0.25, 0.5, 1, 2, 4, and 
24 hours), substrates were rinsed in PBS to remove any 
nonadherent cells and 200 mL of sodium dodecyl sulfate/
Tris (hydroxymethyl) aminomethane hydrochloride solution 
was added into each well to dissolve the fluorescent dye. An 
aliquot (150 mL) from each well was transferred to a new 
96-well plate. Fluorescence was measured using a fluorom-
eter plate reader (Synergy HT; BioTek, Winooski, VT). All 
experiments were performed with a sample size of n = 6.
Immunofluorescence of cytoskeletal actin
Epifluorescence microscopy was used to compare the mor-
phological alterations both in regard to the organization of 
the actin cytoskeleton and cellular shape. The distribution of 
actin was observed at 4 hours, 1 day, and 3 days of culture. 
After this period of time, the cells were washed with PBS 
and fixed in a 4% paraformaldehyde solution for 15 minutes. 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1093
CCN2-loaded titania nanotubes increase fibroblast functionalityInternational Journal of Nanomedicine 2012:7
The samples were then washed in PBS and treated with 
0.1% Triton X-100 (5 minutes at room temperature). The 
samples were then incubated at 37°C for 5 minutes in 1% 
bovine serum albumin/PBS, followed by washing with PBS 
and incubation with phalloidin-fluorescein isothiocyanate   
  (Sigma-Aldrich) for 1 hour at 37°C. Actin staining was visu-
alized and analyzed under a laser scanning confocal micro-
scope (FV1000; Olympus Corporation, Tokyo, Japan).
Statistical analyses
All experiments were run in triplicate (at least) and repeated 
a minimum of three separate times. Experimental data were 
analyzed statistically using analysis of variance followed 
by Student’s t-tests. Statistical significance was considered 
at P , 0.05.
Results
Surface characterization
Scanning electron micrographs (Figure 1A and B) showed 
that the nanotubes were highly ordered and vertically aligned 
with a diameter of approximately 100 nm (20 V voltage) and 
120 nm (25 V voltage). It was estimated that the nanotubes 
were between 400 nm and 500 nm deep from the cross-
sectional image (Figure 1A and B). Representative atomic 
force microscope images of unmodified and 20 V voltage 
nanotubular anodized titanium were characterized by root 
mean square roughness and relative surface area (Figure 2A 
and B; Table 1). The results showed that the unmodified 
titanium surface was relatively smooth compared with the 
100 nm diameter nanotubular anodized titanium surface.
Surface energy calculations from contact angle measure-
ments indicated that the greater surface roughness at the 
nanoscale level correlated with an increased surface energy. 
Specifically, the 100 nm diameter nanotubular titanium had 
a surface energy significantly higher than that of unmodified 
titanium (Table 2).
Analysis of the CCN2 loading efficiency 
and release curve
The loading efficiency was expressed as the percentage 
of loaded drug after washing according to the following 
formula:
η=
- DD
D
0 r
0
where η is loading efficiency, D0 is drug dose used to fill the 
nanotubes, and Dr is the drug dose in the rinse solution.
Loading efficiencies for 100 nm diameter nanotubes 
loaded with 25 ng and 50 ng of CCN2 and 120 nm diam-
eter nanotubes loaded with 50 ng of CCN2 are shown in 
  Figure 3A. These results indicated that 77%, 81%, and 76% 
of the drug, respectively, was retained in the nanotubes after 
an initial wash.
Figure 3B–D show the CCN2 release kinetics from 
the coating in PBS with orbital shaking. The amount of 
released CCN2 diminished gradually with immersion time. 
As expected, there was a slower and more sustained release 
from the 100 nm diameter nanotubes loaded with 50 ng 
CCN2 compared to 100 nm diameter nanotubes loaded with 
25 ng CCN2 and 120 nm diameter nanotubes loaded with 
50 ng. Kinetic analysis of the nanotubes loaded with 50 ng 
of CCN2 indicated that the maximum drug had eluted within 
105 minutes. Alternately, kinetic analysis of the 100 nm diam-
eter nanotubes loaded with 25 ng of CCN2 and the 120 nm 
diameter nanotubes loaded with 50 ng indicated that the 
maximum drug in both had eluted within 90 minutes.
Cell viability
The cell viability of fibroblasts grown on the above substrates 
and the corresponding incubation times are summarized in 
Figure 4. As shown, cell growth on the CCN2-loaded titania 
nanotubular surface was significantly higher than the other 
A B C
S-4800 15.0 kV 12.7 mm × 10.0 k SE(M) 5.00 µm 5.00 µm 1.00 µm S-4800 20.0 kV 7.8 mm × 10.0 k SE(M) S-4800 20.0kV 10.7 mm × 50.0 k SE(M)
Figure 1 Scanning electron microscope images of (A) 20 V voltage nanotubular anodized titanium under low magnification and high magnification, and nanotubular anodized 
titanium cross-sections; (B) 25 V voltage nanotubular anodized titanium under low magnification and high magnification, and nanotubular anodized titanium cross-sections; 
and (C) unmodified titanium.
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two kinds of surfaces at days 1, 3, and 5 after incubation 
(P , 0.05). However, the difference between the nanotubular 
surface and the unmodified surface was not obvious from sta-
tistical analysis. This finding indicates that titania nanotubes 
with a CCN2 coating release growth factor in a sustainable 
manner that promotes cell mitosis continuously.
Fibroblast adhesion
Results of the present study demonstrate increased fibroblast 
adhesion to the CCN2-loaded titania nanotubular surface 
compared to nanotubular titanium and unmodified titanium 
surfaces (Figure 5). There was not a statistically signifi-
cant (P , 0.05) difference in fibroblast adhesion between 
the nanotube anodized titanium compared to unmodified 
titanium. As expected, the results also showed increased 
(P , 0.05) adhesion of fibroblasts to the CCN2-loaded titania 
nanotubular surface.
Morphological alterations and 
cytoskeletal actin
These results showed a strong initial interaction between 
the cells and the modified surface (Figure 6). Notably, the 
morphology of cells grown on these surfaces was different 
after different times during the culturing. At 4 hours, many 
stress fibers were apparent around the periphery of the cells 
on the CCN2-loaded titania nanotubular surface. However, 
the cells grown on the other two kinds of surfaces at this 
point, whilst showing lamella formation, had fewer stress 
fibers. Within 1 day, cells on the CCN2-loaded titania nano-
tubular surface displayed thick, contractile stress fibers. In 
contrast, the cells on the other two surfaces had noticeably 
fewer contractile stress fibers. Within 3 days, cells on the 
CCN2-loaded titania nanotubular surface exhibited thick 
stress fibers and a more voluminous cell body and began 
to become confluent, whereas fewer cells on the other two 
surfaces were confluent.
Discussion
CCN2-loaded titania nanotubular surfaces promoted excel-
lent cellular responses throughout the 5-day study period. 
At 0.25, 0.5, 1, 2, and 4 hours, the number of cells initially 
adhered to the CCN2 coating were higher than the other two 
surfaces. Cells adhered to the implant surfaces by attaching 
to the ECM, and cytoskeletal organization is an important 
criterion of cell–ECM interactions. Cytoskeletal organization 
is also extremely important in modulating cell morphology, 
motility, and adhesion. In the present study, when the cell 
initially responded to the CCN2-coated nanotubular surface, 
the cytoskeleton was formed faster for these cells than for 
those reacting to control surfaces. Additionally, with time, 
denser and thicker parallel-oriented stress fibers were noticed 
on the surface. Therefore, there were most likely more stable 
cell substrate interactions on the CCN2-coated surface.
Infection and epithelial downgrowth are major problems 
with percutaneous implants and both are mainly due to the 
improper closure of the implant–soft tissue interface.16 Most 
current methods are aimed at preventing bacterial infection 
rather than repairing the lack of connective tissue growth 
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Figure 2 Atomic force microscope images of (A) nanotubular anodized titanium (20 V voltage) and (B) unmodified titanium.
Table 1   Surface  roughness  of  unmodified  and  nanotubular 
titanium (20 V voltage) surfaces
Substrates Relative surface 
area (μm2)
Root mean square 
roughness (nm)
Unmodified titanium 0.3260 ± 0.017 6.940 ± 0.75
Nanotubular titanium   0.521 ± 0.045* 9.340 ± 0.59*
Note: *P , 0.05 nanotubular titanium compared with unmodified titanium.
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around the percutaneous site.18,24 A better strategy is to 
create an implant surface with a growth factor coating that 
can promote connective tissue growth around the surgical 
site, which would not only prevent epithelial downgrowth 
but also provide a permanent barrier for bacteria invasion. 
Delivery of drugs locally from an implant surface coating 
rather than systemically can reduce unnecessary side effects 
and the amount of drug required to reach the same or better 
therapeutic efficacy.35 This implant surface with a growth fac-
tor coating not only offers the advantage of a high localized 
drug concentration but is also an effective way of deliver-
ing growth factors directly to the percutaneous site. Several 
previous studies have tried to fabricate implant surfaces with 
growth factor coatings by adsorbing antibiotics or growth 
factors directly to the implant surface with bone cements36,37 
or by loading agents in collagen sponges, porous coatings, or 
polymer-based matrices.38,39 However, all of these approaches 
have shortcomings, which include chemical instability and 
local inflammatory reactions due to material composition.
The titanium nanotube was chosen as the drug carrier 
for making the growth factor coating because it has been 
shown to have good biocompatibility. In addition, previous 
research has clearly proven that nanotube surfaces promote 
bone, skin, and other tissue growth more than current con-
ventional surfaces.16,20–22 Several papers have been published 
that have focused on the applications of titanium nanotube 
drug coatings, but none of them has examined the use of this 
delivery system at the percutaneous site.18,23,24,35 Titanium 
Table 2 Contact angle (in degrees) and surface energy components of unmodified and nanotubular titanium (20 V voltage) surfaces   
(in mJ/m2)
Substrate Contact angle Surface energy components
Water Formamide Diiodomethane λ λs
LW λ λ
+ +
s λ λ
− −
s λ λs
AB λ λs
Unmodified titanium 60.6 52.2 19.3 46.6 0.3 24.8 -5.4 41.2
Nanotubular titanium 28.7 16.2 20.7 47.8 0.4 2.8 7.8 55.6
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Figure 3 (A) Loading efficiency of CNN2 (connective tissue growth factor) in nanotubes; fraction of total CNN2 released from 100 nm diameter nanotubes filled with (B) 
25 ng and (C) 50 ng of CNN2; (D) fraction of total CNN2 released from 120 nm diameter nanotubes filled with 50 ng of CNN2.
Notes: The marked time point on each graph indicates when maximum protein has been released, after which the amount of additional drug eluted was negligible. Concentrations 
at these time points are significantly different from those at time points before (P , 0.05), but were not significantly different from the time points after; n = 3.
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nanotube drug-eluting coatings on the implant surface can 
have a variety of applications. However, the present study just 
focused on their use for percutaneous implants. In the present 
study, these nanotube surfaces showed increased hydrophi-
licity compared to unmodified surfaces. Therefore, these 
surfaces can be easily modified by organic molecules.
Recombinant human CCN2 is an 11.2 kDa C-terminal 
protein that has a positive effect on fibroblasts and is a 
model drug. It has been shown to be sufficient to promote 
fibroblast adhesion via integrins, and it also promotes fibro-
blast proliferation.27–30 CCN2 has also been shown to play a 
key role in mediating the formation of attachments between 
fibroblasts and the ECM at focal adhesions.40 CCN2 gene 
knockout mice also display decreased expression of ECM 
components and matrix metalloproteinases.12 It is envisioned 
that other drugs with fewer detrimental side effects but of a 
similar size could also be loaded into nanotubular titanium to 
improve the interface between the implant and the soft tissue. 
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Figure 4 Cell viability on CCN2 (connective tissue growth factor)-loaded nanotubular titanium, nanotubular titanium, and unmodified titanium surfaces.
Notes: n = 6; *P , 0.05 compared to nanotubular titanium; **P , 0.05 compared to unmodified titanium.
Abbreviations: CNN2, connective tissue growth factor; Ti, titanium.
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Figure 5 Increased fibroblast adhesion to CCN2 (connective tissue growth factor)-loaded nanotubular titanium.
Notes: n = 6; *P , 0.05 compared to nanotubular titanium; **P , 0.05 compared to unmodified titanium.
Abbreviations: CNN2, connective tissue growth factor; Ti, titanium.
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The results of the present study indicate that CCN2 released 
from titania nanotubes improved the functionality of fibro-
blasts on the titanium surface.
In the present study, the nanotubes were 100 nm in 
  diameter. Although a diameter wider than 100 nm may 
significantly allow more solvent and more drug to enter 
the   nanotubes, more drug would be lost during the rinse 
step as a result of the larger diameter and the lower pack-
ing density. Results showed that the loading efficiency and 
release time of 120 nm diameter nanotube were both lower 
than those of the 100 nm diameter nanotube. Another paper 
also demonstrated that larger diameter nanotubes (300 nm) 
can elute less drug than smaller nanotubes (100 nm) of the 
same length.23 Using a simplified lyophilization step to fill the 
nanotubes with CCN2, the loading efficiencies of the drug 
coating groups were both higher than 75%. This means that 
there was little waste in the drug filling process. Other stud-
ies have also shown that the nanotube surface is hydrophilic 
enough for solvents to reach the maximum depth attainable by 
using only a capillary force-dependent filling method. Thus, 
any further improvements in drug loading would require the 
application of another filling method.23
To release protein from the nanotubes, the surfaces were 
immersed in PBS with orbital shaking. The release kinet-
ics showed that the time of release for CCN2 was about 
105 minutes. Some reports have shown elution times over 
weeks for loading with paclitaxel, sirolimus, bovine serum 
albumin, or silver nanoparticles that were seemingly based 
on different sampling without shaking.18,23 Other reports have 
shown similar release times.22,24 The 105 minute-released 
CNN2 mainly enhanced initial adhesion and cytoskeletal 
development of the fibroblast. Rapid and strong adhesion 
CNN2-loaded Ti
AB C
DE F
GH I
4 h
1 d
3 d
Nanotubular Ti Unmodified Ti
Figure 6 Fluorescent images of actin cytoskeleton among fibroblasts reacting to (A, D, and G) CCN2 (connective tissue growth factor)-loaded nanotubular titanium, 
(B, E, and H) nanotubular titanium, and (C, F, and I) unmodified titanium surfaces after (A–C) 4 hours, (D–F) 1 day, and (G–I) 3 days.
Note: Bar = 10 µm.
Abbreviations: CNN2, connective tissue growth factor; d, days; h, hours; Ti, titanium.
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and rapid growth of the fibroblast on the implant surface 
would promote the formation of a permanent liquid bacte-
rial seal in the percutaneous area and would prevent early 
contamination of the implant site,15 which is very important 
for the successful formation of a permanent biologic seal. 
Initial adhesion and cytoskeletal development of the fibro-
blast means rapid growth in the subsequent period, which 
were proven in the results.
In the present study, although the nanotubular titanium 
had greater nanoscale surface roughness and higher surface 
energy than that of unmodified titanium, there were no statisti-
cally significant differences between the unmodified surface 
and the nanotubular surface in regard to fibroblast response. 
Recent reports have shown better cell attachment to nanotu-
bular surfaces that are more hydrophobic than unmodified 
surfaces.20,41,42 But according to some results in the literature, 
fibroblasts prefer a smooth surface to a rough surface.43
To prevent any side effect of CNN2 in the bone healing 
process, a two-stage solution may be a good choice for the 
further clinic application of the CNN2-loaded titania nano-
tube surface on percutaneous implant. This would involve 
initially attaching a conventional component to the bone and 
subsequently, when the wound has already healed, inserting 
the percutaneous component with CNN2-loaded titanium 
nanotube surface.
Conclusion
This study showed the effect of a CCN2-loaded nanotubu-
lar titanium coating on fibroblast functionality. By using a 
simplified lyophilization method, CCN2 was loaded into 
  nanotubes. These titania nanotubes coated with CCN2 under-
went the elution process at a regular release rate with a release 
time of approximately 105 minutes. Moreover, the present 
study provides evidence of enhanced fibroblast adhesion 
and viability due to this CCN2-loaded titania nanotubular 
coated substrate under in vitro conditions, which also pro-
moted actin cytoskeleton organization. The results suggest 
that a CCN2-loaded nanotubular titanium coating may be 
useful for percutaneous implants due to the beneficial effects 
on the formation of a soft tissue biological seal around the 
percutaneous site of the implant surface.
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